Ali Ayberk Beşen

773 total citations
62 papers, 487 citations indexed

About

Ali Ayberk Beşen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Ali Ayberk Beşen has authored 62 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Otorhinolaryngology. Recurrent topics in Ali Ayberk Beşen's work include Inflammatory Biomarkers in Disease Prognosis (19 papers), Head and Neck Cancer Studies (14 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Ali Ayberk Beşen is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (19 papers), Head and Neck Cancer Studies (14 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Ali Ayberk Beşen collaborates with scholars based in Türkiye, United States and Cyprus. Ali Ayberk Beşen's co-authors include Hüseyin Mertsoylu, Erkan Topkan, Uğur Selek, Yurday Özdemir, Ahmet Sezer, Ahmet Küçük, Özgür Özyılkan, Fatih Köse, Berrin Pehlivan and Umut Dişel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ali Ayberk Beşen

58 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Ayberk Beşen Türkiye 13 217 138 113 79 68 62 487
Hüseyin Mertsoylu Türkiye 14 320 1.5× 210 1.5× 78 0.7× 79 1.0× 39 0.6× 64 554
Cui Chen China 17 342 1.6× 125 0.9× 166 1.5× 37 0.5× 80 1.2× 51 772
Raj Singh United States 11 177 0.8× 266 1.9× 111 1.0× 106 1.3× 23 0.3× 50 485
Murat Çaloğlu Türkiye 15 207 1.0× 267 1.9× 164 1.5× 32 0.4× 119 1.8× 51 654
Serdar Soyuer Türkiye 11 124 0.6× 184 1.3× 137 1.2× 52 0.7× 20 0.3× 19 756
Sunil Pasricha India 10 133 0.6× 113 0.8× 73 0.6× 33 0.4× 32 0.5× 94 367
Mert Başaran Türkiye 18 304 1.4× 389 2.8× 222 2.0× 45 0.6× 43 0.6× 85 952
Yun‐Gyoo Lee South Korea 15 436 2.0× 430 3.1× 112 1.0× 49 0.6× 67 1.0× 72 942
Hitoshi Ikushima Japan 16 178 0.8× 295 2.1× 319 2.8× 49 0.6× 56 0.8× 91 921
Haiyan Wang China 14 227 1.0× 320 2.3× 85 0.8× 91 1.2× 21 0.3× 54 939

Countries citing papers authored by Ali Ayberk Beşen

Since Specialization
Citations

This map shows the geographic impact of Ali Ayberk Beşen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Ayberk Beşen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Ayberk Beşen more than expected).

Fields of papers citing papers by Ali Ayberk Beşen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Ayberk Beşen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Ayberk Beşen. The network helps show where Ali Ayberk Beşen may publish in the future.

Co-authorship network of co-authors of Ali Ayberk Beşen

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Ayberk Beşen. A scholar is included among the top collaborators of Ali Ayberk Beşen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Ayberk Beşen. Ali Ayberk Beşen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takashima, Atsuo, Pilar García‐Alfonso, Ali Ayberk Beşen, et al.. (2024). Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. European Journal of Cancer. 205. 114036–114036. 7 indexed citations
2.
Topkan, Erkan, et al.. (2024). Prognostic Value of Novel CARWL Score in Stage IIIC Non‐Small‐Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy. Canadian Respiratory Journal. 2024(1). 2803044–2803044. 2 indexed citations
3.
Somay, Efsun, et al.. (2024). Worth of pan-immune-inflammation value in trismus prediction after concurrent chemoradiotherapy for nasopharyngeal carcinomas. The International Journal of Biological Markers. 39(1). 80–88. 3 indexed citations
4.
5.
Somay, Efsun, Erkan Topkan, Ali Ayberk Beşen, Hüseyin Mertsoylu, & Uğur Selek. (2023). A Comprehensive Review of Differences between Osteoradionecrosis and Medication-related Osteonecrosis of the Jaw. 52–65. 2 indexed citations
6.
Topkan, Erkan, et al.. (2022). High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. SHILAP Revista de lepidopterología. 5 indexed citations
7.
8.
Topkan, Erkan, Yurday Özdemir, Ahmet Küçük, et al.. (2020). Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy. Journal of Oncology. 2020. 1–10. 7 indexed citations
9.
Topkan, Erkan, Ahmet Küçük, Yurday Özdemir, et al.. (2020). Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. Journal of Immunology Research. 2020(1). 8628540–8628540. 35 indexed citations
10.
Topkan, Erkan, Ali Ayberk Beşen, Hüseyin Mertsoylu, et al.. (2020). Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. International Journal of Inflammation. 2020. 1–8. 9 indexed citations
11.
Topkan, Erkan, Hüseyin Mertsoylu, Ahmet Küçük, et al.. (2020). Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterology Research and Practice. 2020. 1–8. 28 indexed citations
12.
Mertsoylu, Hüseyin, et al.. (2019). Chemoradiotherapy-induced Cochlear Toxicity. International Journal of Scientific Research and Management (IJSRM). 7(9).
13.
Özdemir, Yurday, Neşe Torun, Ozan Cem Güler, et al.. (2019). Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases. Journal of bone oncology. 15. 100218–100218. 26 indexed citations
14.
Beşen, Ali Ayberk, et al.. (2014). Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas. Asian Pacific Journal of Cancer Prevention. 15(3). 1333–1337. 6 indexed citations
15.
Sümbül, Ahmet Taner, et al.. (2014). Continuous distress in an oncology clinic in Turkey: should we make use of the distress thermometer mandatory as a precautionary measure for physicians?. PubMed. 19(3). 807–11. 1 indexed citations
16.
Köse, Fatih, Hüseyin Abalı, Ahmet Sezer, et al.. (2012). Patients with advanced cholangiocarcinoma benefit from chemotherapy if they are fit to receive it: single center experience.. PubMed. 16(3). 469–72. 1 indexed citations
17.
Köse, Fatih, Ali Ayberk Beşen, Ahmet Taner Sümbül, et al.. (2011). Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience.. PubMed. 12(5). 1185–8. 19 indexed citations
18.
Dişel, Umut, Serdar Öztuzcu, Ali Ayberk Beşen, et al.. (2010). Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer. 71(1). 109–112. 26 indexed citations
19.
Köse, Fatih, Ali Ayberk Beşen, Saime Paydaş, et al.. (2009). Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats. Clinical and Experimental Nephrology. 14(1). 22–27. 6 indexed citations
20.
Güvenç, Birol, et al.. (2005). Renal Vascular Resistance in Sickle Cell Painful Crisis. International Journal of Hematology. 82(2). 127–131. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hüseyin Mertsoylu Breakdown of academic impact, for papers by Cui Chen Breakdown of academic impact, for papers by Raj Singh Breakdown of academic impact, for papers by Murat Çaloğlu Breakdown of academic impact, for papers by Serdar Soyuer Breakdown of academic impact, for papers by Sunil Pasricha Breakdown of academic impact, for papers by Mert Başaran Breakdown of academic impact, for papers by Yun‐Gyoo Lee Breakdown of academic impact, for papers by Hitoshi Ikushima Breakdown of academic impact, for papers by Haiyan Wang
Rankless by CCL
2026